Showing results (291-300 of 365) with videos related to

Sort By:
Pageof 37
Biochemical and Biophysical Research Communications|August 1, 2016
The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradationChaeuk Chung, Geon Yoo, Tackhoon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2005
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter studyJeeyun Lee, Cheolwon Suh, Yeon Hee Park, et al.
Biochemical and Biophysical Research Communications|July 8, 2017
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinomaByung Soo Lee, Dong Il Park, Da Hye Lee, et al.
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
JAMA Oncology|July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical TrialHee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
The New England Journal of Medicine|September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Cancer Science|July 9, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancerHiroji Iwata, Binghe Xu, Sung-Bae Kim, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancerChanghee Park, Koung Jin Suh, Se Hyun Kim, et al.
Pageof 37